29 registrations that name turmeric and curcumin as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 29 registrations
Status
Phase
29US sites across 11 states
1
2 to 4
5 to 19
20 or more
All 29 registrations
RecruitingNCT05640843
A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)
No phase
Memorial Sloan Kettering Cancer Center
About 180 people
Started Nov 29, 2022
In plain words A study of turmeric and curcumin in people 18 and older, run by Memorial Sloan Kettering Cancer Center. It plans to enroll about 180 people at 8 US sites.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Monoclonal Gammopathy of Undetermined Significance; Smoldering Multiple Myeloma.
Confirmed diagnosis of MGUS or SMM
If non light chain MGUS/SMM then M spike must be either ≥ 0.2 g/dL or BM PC ≥10% (both not required)
If light chain MGUS/SMM then involved must be ≥10 mg/dL or BM PC ≥10% (both not required)
If IgA MGUS/SMM then an IgA level >350 mg/dL and an abnormal immunofixation is required (M spike criteria not required).
5 more inclusion criteria and the exclusion criteria are on the listing.
The researchers are doing this study to look at how butyrate levels change in participants' stool after they are on a- plant-based diet for at least 12 weeks. All participants will have monoclonal gammopathy of undetermined significance (MGUS) or smoldering multiple myeloma (SMM). We will compare how the plant-based diet, omega-3 fatty acid and curcumin supplements, and placebo (an inactive substance that looks like the study supplements) affect butyrate levels in participants' stool.
Where, as registered
8 US sites in 3 states.
RecruitingNCT06055894
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
No phase
Memorial Sloan Kettering Cancer Center
About 200 people
Started Sep 20, 2023
In plain words A study of turmeric and curcumin in people 18 and older, run by Memorial Sloan Kettering Cancer Center. It plans to enroll about 200 people at 7 US sites.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Multiple Myeloma, Smoldering; Multiple Myeloma; Monoclonal Gammopathy of Undetermined Significance.
Confirmed prior diagnosis MGUS or of smoldering myeloma (any time prior). However, confirmation of diagnosis must be documented in their last local oncologist clinic note within 6 months prior to study enrollment.
Age ≥18 years
Willingness to comply with all study-related procedures
Physically able to complete requirements for the study or has someone to assist with the requirements (such as meal preparation, stool shipment and survey completion)
4 more inclusion criteria and the exclusion criteria are on the listing.
The researchers are going this to look at how butyrate levels change in participants' stool after they are on a plant-based diet or dietary supplements (omega-3, curcumin or probiotics) for 2 weeks. All participants will have smoldering multiple myeloma (SMM) or monoclonal gammopathy of undetermined significance (MGUS). The researchers will compare how the different dietary changes affect butyrate levels in participants' stool.
Where, as registered
7 US sites in 2 states.
RecruitingNCT06063486
Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms
Phase 2
University of Southern California
About 30 people
Started Mar 1, 2024
In plain words A Phase 2 study of turmeric and curcumin in people 18 and older, run by University of Southern California. It plans to enroll about 30 people at 2 US sites.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Clonal Cytopenia of Undetermined Significance; Essential Thrombocythemia; Myelodysplastic Syndrome; Myelofibrosis; Polycythemia Vera.
Age >= 18
Eastern Cooperative Oncology Group (ECOG) =< 2
Ability to understand and willingness to sign a written informed consent
Diagnosis of polycythemia vera (PV), essential thrombocytosis (ET) or myelofibrosis (MF) per World Health Organization (WHO) 2016 diagnostic criteria
6 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Biospecimen Collection; Bone Marrow Aspiration; Bone Marrow Biopsy; Curcumin/ Demethoxycurcumin/Bisdemethoxycurcumin-containing Supplement; Piperine Extract (Standardized); Placebo Administration; Questionnaire Administration
Registered summary
This phase II trial evaluates how a curcumin supplement (C3 complex/Bioperine) changes the inflammatory response and symptomatology in patients with clonal cytopenia of undetermined significance (CCUS), low risk myelodysplastic syndrome (LR-MDS), and myeloproliferative neoplasms (MPN). Chronic inflammation drives disease development and contributes to symptoms experienced by patients with CCUS, LR-MDS, and MPN. Curcumin has been shown to have anti-inflammatory and anti-cancer properties and has been studied in various chronic illnesses and hematologic diseases.
Where, as registered
2 US sites in 1 state.
RecruitingNCT02064673
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
Phase 3
yair lotan
About 650 people
Started May 2014
In plain words A Phase 3 study of turmeric and curcumin in male participants 30 to 80, run by yair lotan. It plans to enroll about 650 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists male participants 30 to 80. Conditions: Prostate Cancer.
Status post radical prostatectomy for histologically confirmed adenocarcinoma of the prostate
pathologically confirmed T1-T3 disease
no sign of lymph node or metastatic disease
pT1-pT3pNxMx patients in whom standard NCCN or AUA guidelines would suggest are at low risk for pelvic lymph node or metastatic disease and who would not require confirmatory imaging for metastatic disease.
7 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Curcumin; placebo
Registered summary
This is a prospective study to determine if the adjuvant use of Curcumin improves recurrence-free survival.
Where, as registered
1 US site in 1 state.
RecruitingNCT03769766
Trial of Curcumin to Prevent Progression of Low-risk Prostate Cancer Under Active Surveillance
Phase 3
University of Texas Southwestern Medical Center
About 291 people
Started Mar 11, 2019
In plain words A Phase 3 study of turmeric and curcumin in male participants 40 to 89, run by University of Texas Southwestern Medical Center. It plans to enroll about 291 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists male participants 40 to 89. Conditions: Prostate Cancer.
Age between 40-89 years
Biopsy proven, low-risk, localized prostate cancer (minimum of 8 cores)
May have had biopsy within last 12 months
≤4 separate locations in the prostate involved with cancer. If multiple cores are obtained from same lesion or area than this will count as one location.
4 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Curcumin; Placebo
Registered summary
This is a prospective study to determine if the use of curcumin randomized against placebo will reduce cancer progression in patients with prostate cancer undergoing active surveillance.
Where, as registered
1 US site in 1 state.
RecruitingNCT06531863
Curcumin and EGCG Supplementation to Improve Serum BDNF and Mood Disturbance
Early phase 1
Auburn University
About 64 people
Started Sep 30, 2024
In plain words An early phase 1 study of turmeric and curcumin in people 18 to 50, run by Auburn University. It plans to enroll about 64 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 50; healthy volunteers accepted. Conditions: Mood Disturbance.
Adults age 18-50
Depression subscale score of >9/21 on the DASS-21
No change in medications or supplements over the past 3 months
Can read and speak English
The exclusion criteria are on the listing.
What it tests, as registered
Curcumin; Epigallocatechin Gallate; Placebo
Registered summary
The goal of this randomized placebo controlled trial is to examine mood disturbance and serum brain derived neurotrophic factor (BDNF) in people (age 18-50) with DASS-21 subscale scores \>9. The main questions it aims to answer are: Does curcumin and EGCG supplementation improve mood disturbance symptomology? Does curcumin and EGCG supplementation increase serum BDNF? Researchers will compare intervention versus placebo. Participants will consume an 8-week supplement of both: * 1,330mg/day curcumin * 350mg/day epigallocatechin gallate (EGCG)
Where, as registered
1 US site in 1 state.
RecruitingNCT07063056
Curcumin & Astaxanthin for Lowering Triglyceride Readings and Inflammation
No phase
Medinutra LLC
About 64 people
Started Jul 18, 2025
In plain words A study of turmeric and curcumin in people 21 to 59, run by Medinutra LLC. It plans to enroll about 64 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 21 to 59; healthy volunteers accepted. Conditions: Triglycerides.
Triglyceride reading of 140-250 mg/dL
Age 21-59
The exclusion criteria are on the listing.
What it tests, as registered
Curcumin (Longvida™); Half Dose Curcumin (Longvida™); Astaxanthin; Placebo Control
Registered summary
Two dietary supplements are each being compared to a placebo for the ability to help maintain triglycerides in the normal range. The subjects will be adult men and women with moderately high TG values. Serum triglycerides will be measured before and after 6 weeks of taking 1 capsule per day of either Longvida Curcumin, astaxanthin, or a placebo. A few side blood analysis will also be done. These measures are relevant to low level inflammation.
Where, as registered
1 US site in 1 state.
RecruitingNCT03017118
Turmeric for Patients With Basal Joint Arthritis
No phase
Massachusetts General Hospital
About 60 people
Started Aug 9, 2017
In plain words A study of turmeric and curcumin in people 40 and older, run by Massachusetts General Hospital. It plans to enroll about 60 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 40 and older. Conditions: Thumb Osteoarthritis.
40 years of age or older
English fluency and literacy
Seeking care for basal joint pain
Tender over basal joint
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Turmeric; Placebo
Registered summary
The aim of this study is to assess whether the use of a commercially available nutraceutical, turmeric, is an effective option to manage pain and stiffness in patients with basal joint arthritis. To conduct a pilot Randomized Controlled Trial evaluating the impact of turmeric on basal joint arthritis.
Where, as registered
1 US site in 1 state.
RecruitingNCT07766720
Effects of Eggshell Membrane and Curcumin Extract Supplementation, Separately or Combined, on Recovery From Intense Exercise
No phase
ESM Technologies, LLC
About 60 people
Started Feb 1, 2026
In plain words A study of turmeric and curcumin in male participants 18 to 40, run by ESM Technologies, LLC. It plans to enroll about 60 people at 1 US site.
Agree to refrain from alcohol intake and use of non-steroidal anti-inflammatory (NSAIDS), aspirin, and other over-the-counter pain medications for 48 hours prior to and after completion of each testing session.
The exclusion criteria are on the listing.
What it tests, as registered
NEM® brand eggshell membrane powder; curQ+® brand highly absorbable curcumin; EM Placebo; Curc Placebo; NEM® plus curQ+® combination
Registered summary
Eggshell membrane and Curcumin supplementation prior to intense exercise may reduce inflammation, muscle and joint pain, and promote recovery. This proof-of-concept study will examine how ingestion of specially formulated versions of these nutrients affects recovery from intense exercise.
Where, as registered
1 US site in 1 state.
RecruitingNCT06044025
A Feasibility Study Evaluating a Role for Maintenance Therapy in Patients With Biochemically Progressive Castration Sensitive Prostate Cancer on Intermittent Androgen Deprivation Therapy
Phase 1
University of Arkansas
About 34 people
Started Apr 11, 2024
In plain words A Phase 1 study of turmeric and curcumin in male participants 18 to 100, run by University of Arkansas. It plans to enroll about 34 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists male participants 18 to 100. Conditions: Castration Sensitive Prostate Cancer.
18 years of age or older.
History of prior prostatectomy and/or radiation therapy to the prostate.
Currently have rising PSA levels ≥ 0.2 ng/ml if they have undergone radical prostatectomy, or a PSA ≥ nadir + 2 if they have received only radiotherapy.
Currently have at least 2 consecutively rising serum PSA levels more than 1 week apart
6 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Metformin; Turmeric
Registered summary
The goal of this clinical trial is to assess the feasibility of adding a combination of metformin and turmeric as part of a nutritional intervention regimen to the current standard of care, namely, intermittent Androgen Deprivation Therapy (iADT), for patients with castration sensitive biochemical progressive prostate cancer. The main objectives are: * Assess the feasibility of the study population and enrollment. * Evaluate time to PSA relapse with nutritional intervention on iADT. Participants who are receiving iADT will be dispensed Metformin and turmeric and complete a pill diary. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT06053411
Contribution of UGT2B17 to the Pharmacokinetics of Diclofenac
Early phase 1
Washington State University
About 30 people
Started Mar 1, 2024
In plain words An early phase 1 study of turmeric and curcumin in people 18 to 65, run by Washington State University. It plans to enroll about 30 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 65; healthy volunteers accepted. Conditions: Interaction.
Aged from 18-64 years and healthy
Not taking any medications (prescription and non-prescription) or dietary/herbal supplements known to alter the pharmacokinetics of diclofenac or curcumin
Willing to abstain from consuming caffeinated beverages or other caffeine-containing products the evening before and morning of the first day of each study arm
Willing to abstain from consuming any alcoholic beverages for one day prior to any study day, during the 14-hour inpatient days, and for the outpatient visit(s) following the 14-hour days
3 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Diclofenac; curcumin
Registered summary
The purpose of this pilot study is to gather preliminary data on the (1) contribution of the understudied drug metabolizing enzyme, UDP-glucuronosyltransferase (UGT) 2B17, to the metabolism of a widely used medication, diclofenac, and (2) impact of the UGT2B17 inhibitor and natural product, curcumin, on diclofenac pharmacokinetics. Results will inform future studies aimed to assess the effects of UGT2B17 genetic polymorphisms and co-consumed xenobiotics on the pharmacokinetics and toxicity risk of diclofenac and other UGT2B17 drug substrates.
Where, as registered
1 US site in 1 state.
RecruitingNCT05688488
Clinical Study of Curcumin in Preventing Postoperative Adhesion of Bilateral Vocal Cords
Phase 1 and 2
Eye & ENT Hospital of Fudan University
About 100 people
Starts May 5, 2023 (estimated)
In plain words A Phase 1 and 2 study of turmeric and curcumin in people 18 to 75, run by Eye & ENT Hospital of Fudan University. It plans to enroll about 100 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 75. Conditions: Glottic Web of Larynx; Laryngeal Stenosis; Glottic Carcinoma; Laryngeal Leucoplakia; Laryngeal Polyp; Laryngeal Papilloma.
Patients with bilateral vocal cord diseases who are going to undergo resection of bilateral vocal cord lesions endoscopically.
Patients with bilateral vocal cord adhesion who are going to undergo incision of bilateral vocal cord adhesion endoscopically.
The exclusion criteria are on the listing.
What it tests, as registered
Curcumin; Mitomycin-C
Registered summary
To provide a novel therapy idea and method to solve the clinical problem of postoperative adhesion of bilateral vocal cords, patients enrolled in this study will be applied with curcumin on both wound sites of bilateral vocal cords after the surgery on the bilateral vocal cord endoscopically.
Where, as registered
No US site; China (1).
RecruitingNCT07436130
Curcumin in Critically Ill Patients With Sepsis
No phase
Hospital Civil de Guadalajara
About 56 people
Started Mar 1, 2026
In plain words A study of turmeric and curcumin in people 18 and older, run by Hospital Civil de Guadalajara. It plans to enroll about 56 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Sepsis.
Patients older than 18 years of either sex.
Critically ill patients with a diagnosis of sepsis admitted to the Antiguo Hospital Civil de Guadalajara "Fray Antonio Alcalde."
Patients receiving enteral nutrition.
Written informed consent signed by the patient or their legally authorized representative.
The exclusion criteria are on the listing.
What it tests, as registered
Curcumin; Placebo
Registered summary
Sepsis is a life-threatening condition that occurs when the body's response to an infection becomes overwhelming and damages its own organs. It is one of the leading causes of death in critically ill (very sick) patients worldwide. Despite advances in antibiotics, intensive care, and life-support technologies, sepsis remains difficult to treat because much of the harm comes not only from the infection itself, but from an exaggerated and uncontrolled inflammatory response in the body. The full summary is on the listing.
Where, as registered
No US site; Mexico (1).
RecruitingNCT07241182
Antrodia Cinnamomea Extract Effects on Lung Cancer Patients' Quality of Life During Chemotherapy
No phase
Tri-Service General Hospital (TSGH)
About 40 people
Started Nov 24, 2025
In plain words A study of turmeric and curcumin in people 18 to 99, run by Tri-Service General Hospital (TSGH). It plans to enroll about 40 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 99. Conditions: Lung Cancer (Diagnosis).
Pathologically and radio-graphically diagnosed lung cancer
Age greater than 18 years
Received platinum-based chemotherapy
Life expectancy of six months or longer
The exclusion criteria are on the listing.
What it tests, as registered
Antrodia cinnamomea supplement; Turmeric-Probiotic Group
Registered summary
This randomized trial will test whether Antrodia cinnamomea supplement improves quality of life in lung cancer patients receiving platinum-based chemotherapy. Participants at Tri-Service General Hospital will be randomized to receive either Antrodia cinnamomea capsules or placebo for 3 months, with follow-up to 6 months (24 weeks). Primary outcomes include nausea/vomiting scores, sleep quality, quality of life, and cancer symptoms.
Where, as registered
No US site; Taiwan (1).
RecruitingNCT06080841
Curcumin Supplementation in Cervical Cancer
No phase
National Institute of Cancerología
About 30 people
Started Apr 19, 2023
In plain words A study of turmeric and curcumin in female participants 18 and older, run by National Institute of Cancerología. It plans to enroll about 30 people at 1 site, none in the US.
Understanding the nature of the study and giving a written consent report.
Women > 18 years old.
ECOG performance status: 0-2.
Be willing and able to comply with scheduled visits, treatment plans, and laboratory tests.
9 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Curcumin; Curcumin + Piperine
Registered summary
Brief Summary. The goal of this pilot study is to learn about the effect of curcumin supplementation in locally advanced cervical cancer patients. The main questions it aims to answer are: * Does curcumin supplementation increase the levels of p53 and apoptosis in tumor cells from cervical cancer patients? * At which dose of curcumin supplementation is the broader effect observed for p53 expression and apoptosis in tumor cells from cervical cancer patients? * Are all doses safe for supplementation? Participants will be asked to take curcumin tablets throughout their cancer treatment. The full summary is on the listing.
Where, as registered
No US site; Mexico (1).
RecruitingNCT06932848
The Therapeutic Effect of Curcumin in Nanogels Compared to 0.1% FAO in the Management of Oral Lichen Planus
No phase
Chulalongkorn University
About 30 people
Started Jun 1, 2025
In plain words A study of turmeric and curcumin in people 18 and older, run by Chulalongkorn University. It plans to enroll about 30 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Oral Lichen Planus.
Age 18 years or older
Ability to provide written informed consent
Clinically and histopathologically confirmed diagnosis of erosive or atrophic oral lichen planus (OLP)
Presence of symptoms (NRS pain score > 0 at baseline)
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Curcumin in Nanogels; 0.1% Fluocinolone Acetonide Oral Paste
Registered summary
This randomized, double-blind clinical trial evaluates the therapeutic effects of curcumin in nanogels compared to 0.1% fluocinolone acetonide oral paste in the management of atrophic-erosive oral lichen planus (OLP). The study aims to determine whether curcumin nanogels, a natural treatment with enhanced bioavailability, are as effective and better tolerated than standard corticosteroid therapy.
Where, as registered
No US site; Thailand (1).
RecruitingNCT05947513
Concomitant Curcumin Palliative Radiotherapy in Advanced Cervical Cancer Trial
No phase
Addis Ababa University
About 27 people
Started Apr 10, 2025
In plain words A study of turmeric and curcumin in female participants 18 and older, run by Addis Ababa University. It plans to enroll about 27 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists female participants 18 and older. Conditions: Cervical Cancer.
Age >18 years old (Adult, Older Adult)
Histologically confirmed squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma of the cervix, FIGO stage IIIB-IVA
Undergoing for standard of care palliative radiotherapy without chemotherapy as per the local treatment guideline
Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, 2
4 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Curcumin; Palliative radiotherapy
Registered summary
The goal of this clinical trial is to test curcumin as an adjunct treatment in patients with cervical cancer receiving standard-of-care palliative radiation. The main questions it aims to answer are: 1. Is adding curcumin to standard-of-care palliative radiotherapy of cervical cancer patients feasible? Is conducting this study feasible? 2. Does adding curcumin to standard-of-care palliative radiotherapy of cervical cancer patients improve therapeutic responses? 3. Is adding curcumin to standard-of-care palliative radiotherapy of cervical cancer patients safe? 4. The full summary is on the listing.
Where, as registered
No US site; Ethiopia (1).
Not yet recruitingNCT04266275
Topical Curcumin for HPV Related Cervical Disease
Phase 2
Lisa Flowers
About 200 people
Starts Apr 2027 (estimated)
In plain words A Phase 2 study of turmeric and curcumin in female participants 21 and older, run by Lisa Flowers. It plans to enroll about 200 people at 3 US sites.
Who it lists and where
Who the trial lists, as registered
Lists female participants 21 and older. Conditions: Neoplasm Cervix.
HIV-uninfected and infected women (without current AIDS-defining illness)
Presence of a cervix
Biopsy-proven LSIL disease or recently treated HSIL disease
Adherence to combined anti-retrovirals (cART) if HIV infected
6 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Curcumin C3 Complex; Placebo
Registered summary
The purpose of this study is to see if curcumin can suppress HPV infection in women with low-grade squamous intraepithelial lesions (LSIL) disease or treated high-grade squamous intraepithelial lesions (HSIL) disease. This study plans to explore the effect of curcumin as a potential medical treatment in HIV-uninfected and infected women with mild precancerous lesions of the cervix or recently treated high-grade precancerous lesions at risk for persistent HPV infection. The full summary is on the listing.
Where, as registered
3 US sites in 1 state.
Not yet recruitingNCT06470061
RQC for the Prevention of Alzheimer's Disease and Retinal Amyloid-β
Phase 2
Zaparackas and Knepper LTD
About 200 people
Starts Jul 2024 (estimated)
In plain words A Phase 2 study of turmeric and curcumin in people 50 to 90, run by Zaparackas and Knepper LTD. It plans to enroll about 200 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 50 to 90; healthy volunteers accepted. Conditions: Alzheimer Disease; Mild Cognitive Impairment; Cognitive Decline.
50-90 years of age at screening.
Male or female
Any race or ethnicity.
Provide written informed consent.
4 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Resveratrol, Quercetin, and Curcumin (RQC); Curcumin
Registered summary
The goal of this clinical trial is to evaluate whether oral resveratrol, quercetin, and curcumin (RQC) can prevent the accumulation of retinal amyloid-β and/or cognitive decline over 24 months in adults aged 50-90 with Stage 1 or 2 Alzheimer's disease as described in FDA-2013-D-0077. The trial will also evaluate the safety and tolerability of RQC. Curcumin, which binds to amyloid-β, will act as a fluorescent label to identify retinal amyloid-β in vivo using optical coherence tomography (OCT)-autofluorescence imaging. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
Not yet recruitingNCT06269406
A Combination of Ibuprofen With Curcumin Covered With Liquorice Root Supplementation in the Management of Postoperative Dental Pain in Adults
No phase
S.LAB (SOLOWAYS)
About 264 people
Starts Jul 28, 2025 (estimated)
In plain words A study of turmeric and curcumin in people 18 to 85, run by S.LAB (SOLOWAYS). It plans to enroll about 264 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 85. Conditions: Dental Pain.
Removal of 2 to 4 impacted third molars
The exclusion criteria are on the listing.
What it tests, as registered
ibuprofen 400 mg in combination with Curcumin covered with liquorice root 100 mg; ibuprofen 200 mg in combination with Curcumin covered with liquorice root 100 mg; The combination of ibuprofen 400 mg and placebo in patients after 2-4 molars procedure
Registered summary
Dental pain, a common issue in stomatology, requires a multifaceted treatment approach. This study explores the efficacy of combining Ibuprofen with curcumin and liquorice root supplements for managing postoperative dental pain. Curcumin, known for its antioxidant and anti-inflammatory properties, along with liquorice root, may enhance pain relief beyond conventional NSAIDs like Ibuprofen. This randomized, double-blind, placebo-controlled trial aims to evaluate the safety and effectiveness of this combination therapy in adults undergoing the removal of impacted third molars. The full summary is on the listing.
Where, as registered
No US site; Russia (1).
Not yet recruitingNCT07427914
Effectiveness and Safety of Benemix® in Constipation
No phase
Universidad de Antioquia
About 80 people
Starts Jul 2026 (estimated)
In plain words A study of turmeric and curcumin in people 18 and older, run by Universidad de Antioquia. It plans to enroll about 80 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Constipation - Functional.
Adults (≥18 years old) who use Benemix® for the management of constipation.
Participants who are using the product for the first time.
The exclusion criteria are on the listing.
What it tests, as registered
Benemix®, a functional food composed of turmeric, onion, magnesium, and lactose-free, skimmed milk powder
Registered summary
The goal of this clinical trial is to find out whether the functional food Benemix® helps treat constipation in adults and whether it is safe to use. The main questions this study aims to answer are: Does Benemix® help improve bowel movement frequency and consistency in adults with constipation? What medical problems, if any, do participants experience while taking Benemix®? Adults with constipation will take Benemix® every day for 15 days. During the second week, participants will have either an in-person clinic visit or a telemedicine appointment for checkups and tests. The full summary is on the listing.
Where, as registered
No sites listed yet.
Not yet recruitingNCT07753018
Effects of Curcumin-Piperine Supplementation in Fibromyalgia
Phase 2
Ain Shams University
About 80 people
Starts Aug 1, 2026 (estimated)
In plain words A Phase 2 study of turmeric and curcumin in female participants 18 and older, run by Ain Shams University. It plans to enroll about 80 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists female participants 18 and older. Conditions: Fibromyalgia (FM).
Adult women aged ≥18 years.
Patients with confirmed diagnosis of fibromyalgia, according to 2022 ACR Fibromyalgia criteria.
The exclusion criteria are on the listing.
What it tests, as registered
Curcumin - Piperine; Placebo
Registered summary
The goal of this clinical trail is to evaluate the effectiveness and safety of curcumin-piperine supplementation in patients with fibromyalgia over 3 months compared to placebo. Participants will: Be randomly assigned to receive either curcumin and piperine supplements or a placebo. Attend scheduled clinic visits for clinical assessments and blood sample collection. Complete study questionnaires before and after treatment time frame. The full summary is on the listing.
Where, as registered
No US site; Egypt (1).
Not yet recruitingNCT07248020
A Phase II Single-Arm Study of High-Bioavailability Curcumin as Neoadjuvant Chemoradiotherapy in Mid-to-Low Rectal Cancer: Integrated Clinical and Translational Analysis of Tumor Tissue
Phase 2
Chang Gung Memorial Hospital
About 72 people
Starts Jan 1, 2026 (estimated)
In plain words A Phase 2 study of turmeric and curcumin in people 20 and older, run by Chang Gung Memorial Hospital. It plans to enroll about 72 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 20 and older. Conditions: Rectal Cancer; Locally Advanced Rectal Cancer; Radiation-Induced Enteritis; Radiation Proctitis; Chemoradiotherapy-Related Toxicity.
What it tests, as registered
Curcumin (BCM-95®)
Registered summary
This clinical study investigates the anti-inflammatory and anti-cancer properties of a high-bioavailability formulation of curcumin (BCM-95) in patients with mid-to-low rectal cancer receiving neoadjuvant chemoradiotherapy (nCRT). Curcumin, a polyphenolic compound derived from Curcuma longa, has demonstrated potent anti-inflammatory and anti-neoplastic activities through the modulation of multiple molecular signaling pathways. It has been recognized by the U.S. Food and Drug Administration (FDA) as "Generally Recognized as Safe" (GRAS; GRN No. The full summary is on the listing.
Where, as registered
No US site; Taiwan (1).
Not yet recruitingNCT06758739
Comparison of Curcumin and Intralesional Steroids in Oral Submucous Fibrosis
Phase 3
Services Institute of Medical Sciences, Pakistan
About 70 people
Starts Apr 2025 (estimated)
In plain words A Phase 3 study of turmeric and curcumin in people 18 and older, run by Services Institute of Medical Sciences, Pakistan. It plans to enroll about 70 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Oral Submucous Fibrosis.
Patients diagnosed with Oral submucous fibrosis in accordance with operational definition.
The goal of this clinical trial is to learn if Curcumin is better than Intralesional Steroid Injection for the treatment of oral submucous fibrosis. The main question it aims to answers are: 1. If Curcumin is more effective to improve burning sensation as compared to Intralesional steroid. 2. Does Curcumin treatment results in better mouth opening versus Intralesional steroid. 3. Can Curcumin helps to improve tongue protrusion as compared to Intralesional steroids. Participants will be: * Assessed for one month, two month and three month. The full summary is on the listing.
Where, as registered
No US site; Pakistan (1).
Not yet recruitingNCT06829186
The Effect of Curcumin on Inflammatory Markers in Hemodialysis Patients
Phase 2
University of Guadalajara
About 70 people
Starts Mar 15, 2025 (estimated)
In plain words A Phase 2 study of turmeric and curcumin in people 18 to 100, run by University of Guadalajara. It plans to enroll about 70 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 100. Conditions: Hemodialysis.
Patients of both sexes undergoing dialysis or hemodialysis.
Aged 18 years or older.
Clinically stable and receiving hemodialysis or dialysis for at least three months before study enrollment.
Continuation of pharmacotherapy as prescribed by their physician.
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Curcumin (Longvida™); Placebo
Registered summary
The goal of this clinical trial is to learn if curcumin can lower the inflammation in participants with chronic kidney disease (CKD) undergoing hemodialysis (HD). The main questions it aims to answer are: Does curcumin lower can lower profinflamatory markers in participants with CKD on HD? Researchers will compare curcumin to a placebo (a look-alike substance that contains no drug) to see if curcumin works to help the treatment in participants with CKD on HD. Researchers will compare nutritional status and side effects after taking the supplement. The full summary is on the listing.
Where, as registered
No sites listed yet.
Not yet recruitingNCT06847984
Antimicrobial Effect of Curcumin Versus Chlorohexidine on Oral Microbiome
No phase
Cairo University
About 54 people
Starts Mar 1, 2025 (estimated)
In plain words A study of turmeric and curcumin in people 21 to 45, run by Cairo University. It plans to enroll about 54 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 21 to 45. Conditions: Dental Caries; Dental Plaque Index; Oral Microbiome.
Provide informed consent.
Patients accept the one-year follow-up period.
Cooperative patients.
The study recruited volunteers of both genders
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Curcumin; Chlorohexidine
Registered summary
Dental caries, one of the world's most common infectious diseases, is a biofilm-mediated, sugar-driven, dynamic disease. It has an impact on physical, mental, and social health and is extremely costly to society. It is a complex disease with microbiological, behavioral, genetic, and environmental components. Recently, it has been demonstrated in the literature that the development of dental caries is strongly related with the microbiota in the oral cavity. So, a detailed understanding of caries microbiology is needed. The full summary is on the listing.
Where, as registered
No US site; Egypt (1).
Not yet recruitingNCT06478290
Pilot Assessment of the Safety of a Combination of Curcumin, Omega-3, and Vitamin D Supplements in ACPA+ Individuals
No phase
University of Manitoba
About 50 people
Starts Oct 1, 2025 (estimated)
In plain words A study of turmeric and curcumin in people 18 to 65, run by University of Manitoba. It plans to enroll about 50 people at 2 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 65; healthy volunteers accepted. Conditions: Healthy Participants.
Verified to be ACPA+ based on serum testing
Age 18 to 65 years old
Willing to provide contact information by email, telephone and mailing address
Participant agrees to take the supplements every day for 84 days
6 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
curcumin, omega-3, and vitamin D (COD)
Registered summary
The goal of this clinical trial is to determine if the level of Anti-cyclic citrullinated peptide antibody (ACPA) is altered after taking curcumin, omega-3, and vitamin D supplements (COD) for 3 months. It will also determine the safety and tolerability of COD in the study population. The full summary is on the listing.
Where, as registered
No US site; Canada (2).
Not yet recruitingNCT06752655
Postoperative Pain in Photodynamic Therapy Using Curcumin As a Photosensitizer
No phase
Ataturk University
About 50 people
Starts Jan 2025 (estimated)
In plain words A study of turmeric and curcumin in people 18 to 60, run by Ataturk University. It plans to enroll about 50 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 60; healthy volunteers accepted. Conditions: Periapical Diseases; Postoperative Dental Pain; Irrigation Solution; Photodynamic Therapy (PDT).
healthy patients with aged between 18-60.
Incisor, canine, and premolar teeth that had previously undergone root canal treatment
Incisor, canine, and premolar teeth with a diagnosis of chronic apical abscess or asymptomatic apical periodontitis
teeth with only 1 root canal
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Curcumin with photodynamic thearpy; Control group
Registered summary
In endodontics, various irrigation solutions are used to achieve antibacterial efficacy within the root canal. The antibacterial effect of curcumin-containing root canal solutions, when combined with photodynamic therapy, has been demonstrated in several studies. However, no research has specifically examined their effect on postoperative pain. The aim of this study is to investigate the impact of using a curcumin solution in combination with photodynamic therapy as the final irrigation solution on postoperative pain.
Where, as registered
No US site; Turkey (Türkiye) (1).
Not yet recruitingNCT07379177
Evaluation of the Pharmacokinetics of Curcumin Capsules in Healthy Human
In plain words A study of turmeric and curcumin in people 18 to 65, run by Kingdomway (Inner Mongolia) Nutritional Food Co., Ltd.. It plans to enroll about 12 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 65; healthy volunteers accepted. Conditions: Healthy.
Both men and women are eligible; women must be non-pregnant and non-lactating.
Healthy trial participants aged 18 to 65 years (inclusive of the threshold value).
Body Mass Index (BMI) = weight (kg) / height² (m²), with BMI within the range of 18.5 to 30.0 kg/m² (including the threshold value); male trial participants must have a weight of ≥ 50.0 kg, and female trial participants must have a weight…
Voluntary participants who have signed the informed consent form; the process of obtaining the informed consent form complies with GCP.
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Curcumin; Nanocurcumin
Registered summary
Main objective: Through blood drug concentration testing, evaluate the post-meal pharmacokinetic characteristics of the curcumin product compared to similar products, and assess the differences in body exposure between the self-developed product and the control product in healthy trial participants. Secondary objective: Observe the safety of the self-developed product and the control product in healthy trial participants. Study population: Healthy male individuals or non-pregnant non-lactating females
Where, as registered
No US site; China (1).
ClinicalTrials.gov lists 59 open registrations for this search, including ones where turmeric and curcumin is not a study arm or that are past the 29 we keep. Search them on ClinicalTrials.gov (opens in new tab).